Potential use for the treatment of cardiovascular diseases from traditional herbs: A mini review
Các tác giả
Từ khóa:
thuốc thảo dược, các bệnh lý tim mạch, tác dụng bảo vệ, tăng huyết ápTóm tắt
The prevalence of non-communicable diseases (NCDs), which include cancers, chronic respiratory diseases and cardiovascular disease (CVD), has become a leading health threat to various societies, contributing approximately 60% to the global mortality. Among the three diseases, CVD is labeled as the top cause of deaths, accounting for half of mortality due to NCDs. Risk factors are contributing to the acquisition of CVD that may range from family history, lifestyle, diet and medication. This article aims to deliver a brief literature review concerning efficacies of some traditional herbs in CVD treatment and a current background on this research topic.
Abstract
The prevalence of non-communicable diseases (NCDs), which include cancers, chronic respiratory diseases and cardiovascular disease (CVD), has become a leading health threat to various societies, contributing approximately 60% to the global mortality. Among the three diseases, CVD is labeled as the top cause of deaths, accounting for half of mortality due to NCDs. Risk factors are contributing to the acquisition of CVD that may range from family history, lifestyle, diet and medication. This article aims to deliver a brief literature review concerning efficacies of some traditional herbs in CVD treatment and a current background on this research topic.
Tài liệu tham khảo
[1] G. A. Mensah, G. A. Roth, V. Fuster, “The global burden of cardiovascular diseases and risk factors: 2020 and beyond,” J Am Coll Cardiol, Vol. 74, No. 20, pp. 2529-2532, 2019.
[2] Joint Annual Health Review 2015 (JAHR 2015), “Strengthening prevention and control of non communicable disease”, In Health Mo, 2015.
[3] H. C. Jr. McGill, C. A. McMahan and S. S. Gidding, “Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study,” Circulation, Vol. 117, No. 9, pp. 1216-1227, 2008.
[4] E. Ginter and V. Simko, “Garlic (Allium sativum L.) and cardiovascular diseases,” Bratislavske lekarske listy, Vol. 111, No. 8, pp. 452-456, 2009.
[5] J. Y. Y. Chan, A. C. Y. Yuen, R. Y. K. Chan and S. W. Chan, “A Review of the Cardiovascular Benefits and Antioxidant Properties of Allicin,” Phytotherapy Research, Vol. 27, No. 5, pp. 637-646, 2013.
[6] S. Gorinstein, M. Leontowicz, H. Leontowicz, … S. Trakhtenberg, “Dose-Dependent Influence of Commercial Garlic (Allium sativum) on Rats Fed Cholesterol-Containing Diet,” Journal of Agricultural and Food Chemistry, Vol. 54, No. 11, pp. 4022-4027, 2006.
[7] R. Choudhary, “Beneficial effect of Allium sativum and Allium tuberosum on experimental hyperlipidemia and atherosclerosis,” Pak J Physiol, Vol. 4, No. 2, pp. 7-9, 2008.
[8] A. J. Pulikkottil, “Encyclopedia of Ayurvedic Medicinal Plants,” 2018. [Online]. Available: http://www.indianmedicinalplants.info/medicinalplants-gallery/index.php/Medicinal-Plants-of-America/Allium-sativum-flower (Accessed December 29 2021).
[9] E. Navarro, P. J. Alonso, S. J. Alonso, … M. J. Ayuso, “Cardiovascular activity of a methanolic extract of Digitalis purpurea spp. Heywoodii,” Journal of Ethnopharmacology, Vol. 71, No. 3, pp. 437-442, 2000.
[10] N. Pérez-Alonso, D. Wilken, A. Gerth, … E. Jiménez, “Cardiotonic glycosides from biomass of Digitalis purpurea L. cultured in temporary immersion systems,” Plant Cell, Tissue and Organ Culture (PCTOC), Vol. 99, No. 2, pp. 151-156, 2009.
[11] Digitalis Investigation Group, “The effect of digoxin on mortality and morbidity in patients with heart failure,” N Engl J Med, Vol. 336, No. 8, pp. 525-533, 1997.
[12] C. Roever, J. Ferrante, E. C. Gonzalez, N. Pal and R. G. Roetzheim, “Comparing the toxicity of digoxin and digitoxin in a geriatric popu- lation: should an old drug be rediscovered?,” Southern medical journal, Vol. 93, No. 2, pp. 199-202, 2000.
[13] J. Sullivan, “Digitalis purpurea L.,” 2018. [Online]. Available: https://www.gbif.org/occurrence/1838036565 (Accessed December 29, 2021).
[14] G. Panwar, I. H. Attitalla and S. Guru, “An efficient in vitro clonal propagation and estimation of reserpine content in different plant parts of Rauwolfia serpentina L.,” Am Eurasian J of Sci Res, Vol. 6, No. 4, pp. 217-222, 2011.
[15] S. A. Qureshi, A. Nawaz, S. K. Udani and B. Azmi, “Hypoglycaemic and hypolipidemic activities of Rauwolfia serpentina in alloxan-induced diabetic rats,” IJP - International Journal of Pharmacology, Vol. 5, No. 5, 323-326, 2009.
[16] M. B. Azmi and S. A. Qureshi, “Methanolic Root Extract of Rauwolfia serpentina Benth Improves the Glycemic, Antiatherogenic, and Cardioprotective Indices in Alloxan-Induced Diabetic Mice,” Advances in Pharmacological Sciences, Vol. 2012, pp. 11, 2012.
[17] T. M. Al-Qirim, A. Zafir and N. Banu, “Comparative anti-oxidant potential of Rauwolfia serpentina and Withania somnifera on cardiac tissues,” The FASEB Journal, Vol. 21, No. 5, pp. 271, 2007.
[18] Therapeutes magazine “Rauwolfia serpentina: Propriétés, Bienfaits, Utilisations,” 2021. [Online]. Available: https://therapeutes magazine.com/rauwolfia-serpentina/ (Accessed December 29, 2021).
[19] T. M. Wong, S. Wu, X. C. Yu and H. Y. Li, “Cardiovascular actions of Radix Stephaniae tetrandrae: a comparison with its main component, tetrandrine,” Acta pharmaco-logica Sinica, Vol. 21, No. 12, pp. 1083-1088, 2000.
[20] K. Kawashima, T. Hayakawa, Y. Miwa, … Z. Chen, “Structure and hypotensive activity relationships of tetrandrine derivatives in stroke-prone spontaneously hypertensive rats,” General Pharmacology: The Vascular System, Vol. 21, No. 3, pp. 343-347, 1990.
[21] J. Q. Qian, “Cardiovascular pharma-cological effects of bisbenzyliso-quinoline alkaloid derivatives,” Acta Pharmacol Sin, Vol. 23, No. 12, pp. 1086-1092, 2002.
[22] Available: http://www.innerpath.com.au/matmed/herbs/Stephania~tetrandra.htm (Accessed December 29, 2021).
[23] Z. C. Koçyõldõz, H. Birman, V. Olgaç, … A. H. Meriçli, “Crataegus tanacetifolia leaf extract prevents L-NAME-induced hypertension in rats: a morphological study,” Phytotherapy Research, Vol. 20, No. 1, pp. 66-70, 2006.
[24] J. N. Wang, J. X. Liu, X. Z. Li and X. H. Shang, “The effect of two active ingredients proportion in leaf of the Crataegus pinnatifida Bunge var. major NE Br. on cardiovascular hemodynamics of anaesthetic dogs,” Chinese New Drugs Journal, Vol. 13, pp. 609-612, 2004.
[25] C. Y. Kwok, C. N. Y. Wong, M. Y. C. Yau, … S. W. Chan, “Consumption of dried fruit of Crataegus pinnatifida (hawthorn) suppresses high-cholesterol diet-induced hypercholesterolemia in rats,” Journal of Functional Foods, Vol. 2, No. 3, pp. 179-186, 2010.
[26] M. Freed, “Hawthorn: Heart Healing from Physical to Spiritual,” 2021. [Online]. Available: https://traditionalroots.org/hawthorn-heart-healing-from-physical-to-spiritual/ (Accessed December 29, 2021).
[27] X. Ouyang, K. Takahashi, K. Komatsu, … J. Azuma, “Protective effect of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cells,” The Japanese Journal of Pharmacology, Vol. 87, No. 4, pp. 289-296, 2001.
[28] K. Takahashi, X. Ouyang, K. Komatsu, … J. Azuma, “Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells,” Biochemical Pharmacology, Vol. 64, No. 4, pp. 745-750, 2002.
[29] Available: https://api.gbif.org/v1/image/unsafe/http%3A%2F%2Fcollections.nmnh.si.edu%2Fmedia%2Findex.php%3Firn%3D10908 074 (Accessed December 29, 2021).
[30] M. S. Afonso, A. M. de O Silva, E. B. Carvalho, … J. Mancini-Filho, “Phenolic compounds from Rosemary (Rosmarinus officinalis L.) attenuate oxidative stress and reduce blood cholesterol concentrations in diet-induced hypercholesterolemic rats,” Nutrition & Metabolism, Vol. 10, No. 1,pp. 1, 2013.
[31] W. Wang, N. Wu, Y. G. Zu and Y. J. Fu, “Antioxidative activity of Rosmarinus officinalis L. essential oil compared to its main components,” Food Chemistry, Vol. 108, No. 3, pp. 1019-1022, 2008.
[32] H. de Vries and M. Lemmens, “Rosmarinus officinalis L.,” 2020. [Online]. Available: https://www.gbif.org/occurrence/2834872541 (Accessed December 29, 2021).
[33] D. Grassi, G. Desideri, G. Croce, … C. Ferri, “Flavonoids, vascular function and cardiovascular protection,” Curr Pharm Des, Vol. 15, No. 10, pp. 1072-1084, 2009.
[34] A. Z'Brun, “Ginkgo--myth and reality,” Praxis, Vol. 84, No. 1, pp. 1-6, 1995.
[35] M. Rodriguez, L. Ringstad, P. Schafer, … G. Siegel, “Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients,” Atherosclerosis, Vol. 192, No. 2, pp. 438-444, 2007.
[36] D. C. Ren, G. H. Du, J. T. Zhang, “Protective effect of Ginkgo biloba extract on endothelial cell against damage induced by oxidative stress,” J Cardiovasc Pharmacol, Vol. 40, No. 6, pp. 809-14, 2002.
[37] S. Lim, J. W. Yoon, S. M. Kang, … K. S. Park, “EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes,” PLoS One, Vol. 6, No. 6, e20301, 2011.
[38] Shimohuri, “Ginkgo biloba L.,” 2021. [Online]. Available: https://www.gbif.org/occurrence/3097423676 (Accessed December 29, 2021).
[39] B. Kammerer, R. Kahlich, C. Biegert, C. H. Gleiter and L. Heide, “HPLC-MS/MS analysis of willow bark extracts contained in pharma-ceutical preparations,” Phytochem Anal, Vol. 16, No. 6, pp. 470-478, 2005.
[40] C. Truong, “Low-dose acetylsalicylic acid for primary prevention of cardiovascular disease: Do not misinterpret the recom-mendations,” Can Fam Physician, Vol. 61, No. 11, pp. 971-972, 2015.
[41] iNaturalist contributors, iNaturalist, “Salix alba L.,” 2021. [Online]. Available: https://www.gbif.org/occurrence/1841205784 (Accessed December 29, 2021).
[42] J. Wang, X. R. Liu and Y. N. Shi, “Observation of the preventive and therapeutic effect of Chuanxiong on the atherosclerosis of rabbits,” Chinese Journal of Integrated Traditional and Western Medicine, Vol. 1, No. 1, pp. 52-55, 1995.
[43] M. Li, S. Handa, Y. Ikeda and S. Goto, “Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine 'Chuanxiong,' on platelet thrombus formation under high shear rates,” Thromb Res, Vol. 104, No. 1, pp. 15-28, 2001.
[44] M. Li, C. Zhao, R. N. Wong, … F. Liao, “Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B,” Clin Hemorheol Microcirc, Vol. 31, No. 2, pp. 97-103, 2004.
[45] C. Y. Cheng, T. Y. Ho, E. J. Lee, … C. L. Hsieh, “Ferulic acid reduces cerebral infarct through its antioxidative and anti-inflammatory effects following transient focal cerebral ischemia in rats,” Am J Chin Med, Vol. 36, No. 6, pp. 1105-1119, 2008.
[46] Available: http://hermionesgarden.blogspot.com/2011/05/ligusticum-porteri-osha.html (Accessed December 29, 2021).
Tải xuống
Tải xuống: 28
